H-3B6527 is under clinical development by H3 Biomedicine and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase I drugs for Bile Duct Cancer (Cholangiocarcinoma) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how H-3B6527’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

H-3B6527 overview

H-3B6527 is under development for the treatment of intrahepatic cholangiocarcinoma. It is administered orally. The drug candidate acts by targeting fibroblast growth factor receptor 4 (FGFR4).

It was also under development for hepatocellular carcinoma.

H3 Biomedicine overview

H3 Biomedicine Inc (H3 Biomedicine), a subsidiary of Eisai Co Ltd, is a biopharmaceutical company that offers therapies. The company concentrates on discovery and early development of novel, targeted anti-cancer compounds. It is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of H-3B6527’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.